Synchronised infection identifies early rate-limiting steps in the hepatitis B virus life cycle.


Journal

Cellular microbiology
ISSN: 1462-5822
Titre abrégé: Cell Microbiol
Pays: India
ID NLM: 100883691

Informations de publication

Date de publication:
12 2020
Historique:
received: 06 04 2020
revised: 15 07 2020
accepted: 27 07 2020
pubmed: 18 8 2020
medline: 7 8 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Hepatitis B virus (HBV) is an enveloped DNA virus that contains a partially double-stranded relaxed circular (rc) DNA. Upon infection, rcDNA is delivered to the nucleus where it is repaired to covalently closed circular (ccc) DNA that serves as the transcription template for all viral RNAs. Our understanding of HBV particle entry dynamics and host pathways regulating intracellular virus trafficking and cccDNA formation is limited. The discovery of sodium taurocholate co-transporting peptide (NTCP) as the primary receptor allows studies on these early steps in viral life cycle. We employed a synchronised infection protocol to quantify HBV entry kinetics. HBV attachment to cells at 4°C is independent of NTCP, however, subsequent particle uptake is NTCP-dependent and reaches saturation at 12 h post-infection. HBV uptake is clathrin- and dynamin dependent with actin and tubulin playing a role in the first 6 h of infection. Cellular fractionation studies demonstrate HBV DNA in the nucleus within 6 h of infection and cccDNA was first detected at 24 h post-infection. Our studies show the majority (83%) of cell bound particles enter HepG2-NTCP cells, however, only a minority (<1%) of intracellular rcDNA was converted to cccDNA, highlighting this as a rate-limiting in establishing infection in vitro. This knowledge highlights the deficiencies in our in vitro cell culture systems and will inform the design and evaluation of physiologically relevant models that support efficient HBV replication.

Identifiants

pubmed: 32799415
doi: 10.1111/cmi.13250
pmc: PMC7611726
mid: EMS135042
doi:

Substances chimiques

DNA, Viral 0
RNA, Viral 0
Symporters 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13250

Subventions

Organisme : Medical Research Council
ID : MR/R022011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100247
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200838
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0801976
Pays : United Kingdom
Organisme : Wellcome Trust
ID : IA 200838/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400802
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd.

Références

J Cell Biol. 1980 Feb;84(2):404-20
pubmed: 6991511
Nat Commun. 2017 Jul 25;8(1):125
pubmed: 28743900
J Virol. 2007 Jun;81(12):6164-74
pubmed: 17409153
PLoS One. 2015 Jun 12;10(6):e0129889
pubmed: 26070202
Liver Int. 2017 Jan;37 Suppl 1:45-51
pubmed: 28052621
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4244-53
pubmed: 25201958
J Cell Biol. 1987 Oct;105(4):1473-8
pubmed: 3312229
J Hepatol. 2019 Oct;71(4):834-839
pubmed: 31302176
Cell Microbiol. 2009 Feb;11(2):249-60
pubmed: 19016777
Gastroenterology. 2019 Jan;156(2):369-383
pubmed: 30267712
Virology. 2005 Jul 20;338(1):53-60
pubmed: 15936793
Antimicrob Agents Chemother. 2019 Dec 20;64(1):
pubmed: 31658963
Cell Host Microbe. 2016 Jul 13;20(1):25-35
pubmed: 27321908
Dev Cell. 2006 Jun;10(6):839-50
pubmed: 16740485
J Virol. 2014 Nov;88(22):13378-95
pubmed: 25210183
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):362-74
pubmed: 27075261
J Gen Virol. 1999 Aug;80 ( Pt 8):2127-2135
pubmed: 10466812
Small. 2011 May 9;7(9):1212-8
pubmed: 21456082
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9849-54
pubmed: 12909718
PLoS Pathog. 2018 Jun 21;14(6):e1007124
pubmed: 29928064
Methods Mol Biol. 2017;1540:15-25
pubmed: 27975304
Virol J. 2015 Nov 16;12:190
pubmed: 26573723
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15655-60
pubmed: 12432097
J Virol. 2019 Sep 30;93(20):
pubmed: 31375584
Cold Spring Harb Perspect Biol. 2014 Aug 01;6(8):
pubmed: 25085912
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
J Virol. 2009 Jan;83(1):440-53
pubmed: 18971266
J Gastroenterol Hepatol. 2016 Feb;31(2):302-9
pubmed: 26414381
J Virol. 2010 Jan;84(1):243-53
pubmed: 19846513
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
Viruses. 2018 Mar 31;10(4):
pubmed: 29614729
J Virol. 2012 Sep;86(17):9443-53
pubmed: 22740403
J Virol. 2017 Mar 13;91(7):
pubmed: 28100610
Hepatology. 2017 Sep;66(3):703-716
pubmed: 28195359
J Cell Biol. 1999 Apr 5;145(1):45-55
pubmed: 10189367
J Virol. 2009 Oct;83(19):9652-62
pubmed: 19625407
Virus Evol. 2020 Aug 25;7(1):veaa063
pubmed: 33732502
Cell. 2011 Aug 5;146(3):471-84
pubmed: 21816279
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492
pubmed: 30952782
J Gen Virol. 2016 Jan;97(1):121-127
pubmed: 26474824
Sci Rep. 2017 Nov 30;7(1):16616
pubmed: 29192196
Nat Microbiol. 2020 May;5(5):715-726
pubmed: 32152586
Viruses. 2017 Jan 21;9(1):
pubmed: 28117723
Intervirology. 2014;57(3-4):151-7
pubmed: 25034482
Nat Commun. 2017 Dec 15;8(1):2146
pubmed: 29247188
Int J Mol Sci. 2014 Feb 19;15(2):2892-905
pubmed: 24557582
J Virol. 2004 Aug;78(15):8289-300
pubmed: 15254201
J Virol. 2010 Feb;84(4):1989-2000
pubmed: 20007265
Cell Microbiol. 2020 Aug;22(8):e13205
pubmed: 32216005
Antiviral Res. 2018 Oct;158:185-198
pubmed: 30145242
Sci Rep. 2020 Aug 24;10(1):14101
pubmed: 32839523
Cell Struct Funct. 1999 Oct;24(5):329-35
pubmed: 15216890
Nat Cell Biol. 2016 Dec 23;19(1):1-9
pubmed: 28008184
J Cell Biol. 2002 Nov 11;159(3):441-52
pubmed: 12417576
J Clin Invest. 2010 Mar;120(3):924-30
pubmed: 20179355
J Immunol Methods. 1999 Jan 1;222(1-2):197-208
pubmed: 10022386
Eur J Cell Biol. 1993 Jun;61(1):44-53
pubmed: 8223707
Ann Transplant. 2018 Nov 13;23:789-801
pubmed: 30420590
J Hepatol. 2018 Dec;69(6):1231-1241
pubmed: 30142426
Hepatology. 2007 Dec;46(6):1759-68
pubmed: 18046710
FEBS Lett. 2016 Jul;590(13):1915-26
pubmed: 27149321
Antiviral Res. 2013 Feb;97(2):195-7
pubmed: 23266293
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558
pubmed: 30981686
J Hepatol. 2016 Apr;64(1 Suppl):S17-S31
pubmed: 27084033
Hepatology. 2018 Aug;68(2):751-762
pubmed: 29331069
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):192-202
pubmed: 29870733
Virology. 2016 Oct;497:23-32
pubmed: 27420796
Hepatology. 2013 Mar;57(3):985-94
pubmed: 23161433
PLoS One. 2015 Jun 16;10(6):e0128401
pubmed: 26079492
J Hepatol. 2016 Apr;64(1 Suppl):S32-S40
pubmed: 27084034

Auteurs

Anindita Chakraborty (A)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.
Technical University of Munich, Institute for Advanced Study, Munich, Germany.

Chunkyu Ko (C)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.

Christin Henning (C)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.

Aaron Lucko (A)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.

James M Harris (JM)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Fuwang Chen (F)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.

Xiaodong Zhuang (X)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Jochen M Wettengel (JM)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.

Stephanie Roessler (S)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Ulrike Protzer (U)

Institute of Virology, Technical University of Munich, School of Medicine/Helmholtz Zentrum München, Munich, Germany.
Technical University of Munich, Institute for Advanced Study, Munich, Germany.
German Center for Infection Research (DZIF), Munich, Germany.

Jane A McKeating (JA)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH